



(12) Translation of
European patent specification

(11) NO/EP 3315131 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/47 (2006.01)
A61P 11/00 (2006.01)
C07D 215/50 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.11.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.09.14
(86)	European Application Nr.	16814513.4
(86)	European Filing Date	2016.06.24
(87)	The European Application's Publication Date	2018.05.02
(30)	Priority	2015.06.25, JP, 2015127788
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
	Designated Validation States:	MA; MD
(73)	Proprietor	Taiho Pharmaceutical Co., Ltd., 1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan
(72)	Inventor	FUJIOKA, Akio, c/o Taiho Pharmaceutical Co., Ltd.3 Okubo, Tsukuba-shilbaraki 300-2611, Japan
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	THERAPEUTIC AGENT FOR FIBROSIS
(56)	References Cited:	JP-A- 2011 500 778 JP-A- 2003 238 592 EP-A1- 1 466 624 JP-A- 2013 518 887 WO-A1-2009/125597 JP-A- 2009 518 296 JP-A- 2013 529 207 ZHAO LU ET AL: "Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhou gastric cancer", CANCER SCIENCE, vol. 104, no. 12, December 2013 (2013-12), pages 1640- 1646, XP002787868,

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3315131

1

Patentkrav

- 5 1. 4-[2-fluor-4-[[[(2-fenylacetyl)amino]tioksometyl]amino]-fenoksy]-7-metoksy-N-metyl-6-kinolinkarboksamid eller et salt derav, for anvendelse i behandling av fibrose.
- 10 2. 4-[2-fluor-4-[[[(2-fenylacetyl)amino]tioksometyl]amino]-fenoksy]-7-metoksy-N-metyl-6-kinolinkarboksamid eller et salt derav for anvendelse ifølge krav 1, hvori fibrosen er lungefibrose.
3. 4-[2-fluor-4-[[[(2-fenylacetyl)amino]tioksometyl]amino]-fenoksy]-7-metoksy-N-metyl-6-kinolinkarboksamid eller et salt derav for anvendelse ifølge krav 1, hvori fibrosen er interstitiell pneumoni ledsaget av vevsfibrose.
- 15 4. 4-[2-fluor-4-[[[(2-fenylacetyl)amino]tioksometyl]amino]-fenoksy]-7-metoksy-N-metyl-6-kinolinkarboksamid eller et salt derav for anvendelse ifølge krav 1, hvori fibrosen er idiopatisk lungefibrose.
- 20 5. Farmasøytisk sammensetning for anvendelse i behandling av fibrose, omfattende 4-[2-fluor-4-[[[(2-fenylacetyl)amino]tioksometyl]amino]-fenoksy]-7-metoksy-N-metyl-6-kinolinkarboksamid eller et salt derav og en farmasøytisk akseptabel bærer.
- 25 6. Den farmasøytiske sammensetningen for anvendelse ifølge krav 5, hvori fibrosen er lungefibrose.
7. Den farmasøytiske sammensetningen for anvendelse ifølge krav 5, hvori fibrosen er interstitiell pneumoni ledsaget av vevsfibrose.
- 30 8. Den farmasøytiske sammensetningen for anvendelse ifølge krav 5, hvori fibrosen er idiopatisk lungefibrose.